Diabetes Research Institute Announces Revolutionary Transplantation Approach to Treating Type 1 Diabetes at ADA 2024

“Our observations highlight the transformative potential of combining stem cell-derived islets with an immunomodulatory microgel,” said Dr. Lanzoni. “This approach could enable transplantation across the allogeneic barrier, providing a scalable and durable solution for T1D, and could improve the long-term safety and efficacy of islet cell transplantation.” »

“The Accelerated Testing Facility at the DRI Cell Transplant Center continues to serve as a key shared resource for validating emerging technologies for a cure for diabetes,” said Camillo Ricordi, MD, director of the Cell Transplant Center and director emeritus of Diabetes. Research Institute as well as head of the division of cell transplantation at the Miller School. “We hope to continue to contribute to the identification of reliable and potentially unlimited stem cell-derived islet sources for transplantation, which may one day be able to replace the limited availability of pancreas-derived islets from multi-donor donors. organs, when permanent immunosuppression of the recipient is no longer necessary. »